+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
All Ages
All Genders
ID05574296

Testing Safety and Feasibility of Inhaled Hydrogen Gas During Extracorporeal Cardiopulmonary Resuscitation in Children and Young Adults with Cardiac Arrest

Led by Boston Children's Hospital · Updated on 2025-07-03

53

Participants Needed

4

Research Sites

21 weeks

Total Duration

AI-Summary

What This Trial Is About

This research aims to test the feasibility and safety of inhaled hydrogen gas H2 as a rescue therapy during cardiac arrest requiring extracorporeal cardiopulmonary resuscitation ECPR in patients with cardiac conditions like congenital heart disease. The trial addresses the challenge of neurologic and kidney injuries caused by ischemia and reperfusion during ECPR. Preclinical studies showed that hydrogen inhalation may reduce damage after ischemic events, and early human safety studies found no significant adverse effects from inhaling 2.4% hydrogen gas. Participants are randomly assigned to one of two groups usual care alone or usual care plus inhaled 2% hydrogen gas administered via mechanical ventilator and ECMO membrane for 72 hours. This early-phase, single-blind randomized trial includes a small initial phase and will enroll patients undergoing ECPR for refractory cardiac arrest. The hydrogen gas dosing is continuous during the first 72 hours after resuscitation, with oxygen levels adjusted by the clinical team. During the study, researchers will monitor how well the hydrogen gas can be delivered, safety over 30 days, and secondary measures such as survival to hospital discharge, duration of ICU and hospital stays, and functional status up to 12 months. Participants are closely observed in cardiac intensive care, with assessments including safety events and feasibility of treatment administration. The total participation duration includes 30 days for safety monitoring and up to 12 months for longer-term outcomes.

CONDITIONS

Brief Title

Hydrogen's Feasibility and Safety as a Therapy in ECPR

Research Team

J

John N Kheir, MD

V

Victoria Habet, DO

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here